Study on influencing factors of anti-tuberculosis drug-induced liver injury in pulmonary tuberculosis patients complicated with diabetes mellitus

doi:10.19982/j.issn.1000-6621.20210545

Abstract

Abstract:

Objective: To analyze the influencing factors of anti-tuberculosis drug-induced liver injury (ATB-DILI) in patients with pulmonary tuberculosis complicated with diabetes mellitus (PTB-DM). Methods: A prospective cohort study was conducted to continuously enroll 458 inpatients with PTB-DM who met the enrollment criteria from October 2017 to March 2019 in the North Branch of Qingdao Central Hospital. Before their treatment, we collected information of age, gender, marital status, education level, occupation, diet, smoking, drinking, physical activity level, clinical symptoms of tuberculosis, body mass index, blood biochemical index, blood routine index, blood glucose control level,usage and types of liver protection drugs through a self-designed structured questionnaire; after following-up for eight months, a multivariate Cox proportional hazard regression was done to analyze the occurrence of ATB-DILI and its influencing factors. Results: Among 458 PTB-DM patients,53 patients developed ATB-DILI, with an incidence rate of 11.6%. After adjusting for confounding factors such as smoking, physical activity, liver protection drugs and anemia, it was found that poor glycemic control (HR (95%CI)=2.787 (1.256-6.183)), drinking (HR (95%CI)=2.159 (1.097-4.251)), low weight (body mass index <18.5) (HR (95%CI)=2.808 (1.391-5.670)) and insufficient dietary diversity (HR (95%CI)=3.199 (1.372-7.459)) were risk factors for ATB-DILI in PTB-DM patients. Conclusion: Patients with PTB-DM were prone to develop ATB-DILI after anti-tuberculosis treatment, especially for those who had drinking habits, with low weight and inadequate dietary diversity, they were associated with a higher risk of ATB-DILI.

Key words: Tuberculosis,pulmonary, Diabetes mellitus, Drug-induced liver injury, Comorbidity, Factor analysis,statistical

CLC Number:

ZHANG Yang-ting, LU Xue-zhao, LI Xiao-na, ZHONG Zhao-yi, WANG Na, CAI Jing, MA Ai-guo, LIU Yu-feng, WANG Qiu-zhen. Study on influencing factors of anti-tuberculosis drug-induced liver injury in pulmonary tuberculosis patients complicated with diabetes mellitus[J]. Chinese Journal of Antituberculosis, 2022, 44(1): 64-70. doi: 10.19982/j.issn.1000-6621.20210545

Figures/Tables 5

临床指标	肝损伤组(53例)	无肝损伤组(405例)	统计检验值	P值
结核病特征性表现[例(发生率,%)]
咳嗽	48(90.6)	365(90.6)	χ²=0.000	1.000
咳痰	45(84.9)	325(80.6)	χ²=0.556	0.456
咯血	8(15.1)	53(13.2)	χ²=0.153	0.696
发热	19(35.8)	141(35.0)	χ²=0.015	0.902
乏力	22(41.5)	177(43.9)	χ²=0.111	0.739
盗汗	17(32.1)	120(29.8)	χ²=0.118	0.731
胸痛	12(22.6)	69(17.1)	χ²=0.977	0.323
食欲减退	10(18.9)	51(12.7)	χ²=1.560	0.212
胸闷	22(41.5)	184(45.7)	χ²=0.325	0.568
血脂异常[例(发生率,%)]
高甘油三酯血症	3(5.7)	28(6.9)	χ²=0.117	0.733
高胆固醇血症	1(1.9)	21(5.2)	χ²=1.115	0.291
混合型高脂血症	3(5.7)	9(2.2)	χ²=2.171	0.141
低高密度脂蛋白血症	24(45.3)	115(28.4)	χ²=6.323	0.012
总蛋白(g/L, $x ¯$ ±s)	66.00±7.69	66.71±7.25	t=0.454	0.524
白蛋白(g/L, $x ¯$ ±s)	36.81±5.45	39.78±12.39	t=3.144	0.099
低蛋白血症[例(发生率,%)]	6(11.3)	25(6.2)	χ²=1.968	0.161
贫血[例(发生率,%)]	20(37.7)	85(21.0)	χ²=7.440	0.006
空腹血糖^a(mmol/L, $x ¯$ ±s)	12.36±4.67	9.45±3.52	t=-4.184	<0.001
血糖控制不良^a[例(发生率,%)]	40(83.3)	260(68.2)	χ²=4.617	0.032

膳食多样化	肝损伤(53例)	无肝损伤(305例)^a	统计检验值	P值
膳食多样化评分(分, $x ¯$ ±s)	6.49±2.08	7.47±1.64	t=3.812	<0.001
膳食多样性[例(构成比,%)]			χ²=8.698	0.013
不足	7(13.2)	16(5.2)
适中	16(30.2)	61(20.0)
充足	30(56.6)	228(74.8)

变量	β值	s $x ¯$ 值	Wald χ²值	P值	HR(95%CI)值
血糖控制不良	1.025	0.407	6.355	0.012	2.787(1.256~6.183)
吸烟	-0.432	0.344	1.570	0.210	0.649(0.331~1.276)
饮酒	0.770	0.346	4.959	0.026	2.159(1.097~4.251)
中/重体力活动	-0.455	0.344	1.743	0.187	0.635(0.323~1.246)
使用保肝药情况	—0.432	0.405	1.140	0.286	0.649(0.294~1.435)
消瘦(体质量指数<18.5)	1.032	0.359	8.294	0.004	2.808(1.391~5.670)
贫血	0.420	0.305	1.902	0.168	1.522(0.838~2.765)
膳食多样性不足	1.163	0.432	7.244	0.007	3.199(1.372~7.459)

References 32

[1]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021, 43(1):12-22. doi: 10.3969/j.issn.1000-6621.2021.01.004. doi: 10.3969/j.issn.1000-6621.2021.01.004
[2]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global Brevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4):e448-e460. doi: 10.1016/S2214-109X(18)30487=X. doi: 10.1016/S2214-109X(18)30487=X URL
[3]	Al-Rifai RH, Pearson F, Critchley JA, et al. Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PLoS One, 2017, 12(11):e0187967. doi: 10.1371/journal.pone.0187967. doi: 10.1371/journal.pone.0187967
[4]	Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract, 2018, 138:271-281. doi: 10.1016/j.diabres.2018.02.023. doi: 10.1016/j.diabres.2018.02.023 URL
[5]	Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005, 112(17):2735-2752. doi: 10.1161/CIRCULATIONAHA.105.169404. doi: 10.1161/CIRCULATIONAHA.105.169404 pmid: 16157765
[6]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版). 中国实用内科杂志, 2018, 38(4):292-344. doi: 10.19538/j.nk2018040108. doi: 10.19538/j.nk2018040108
[7]	卫生部疾病预防控制局, 卫生部医政司, 中国疾病预防控制中心. 中国结核病防治规划实施工作指南(2008年版). 北京: 中国协和医科大学出版社, 2009: 7.
[8]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09.
[9]	中华医学会结核病学分会. 抗结核药物性肝损伤诊治指南(2019版). 中华结核和呼吸杂志, 2019, 42(5):343-356. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007. doi: 10.3760/cma.j.issn.1001-0939.2019.05.007
[10]	沈嘉, 陈超刚, 张敬聪, 等. 糖尿病前期患者膳食多样化评分与糖尿病发病的关联分析. 中国食物与营养, 2018, 24(4):71-75. doi: 10.3969/j.issn.1006-9577.2018.04.016. doi: 10.3969/j.issn.1006-9577.2018.04.016
[11]	中国营养学会. 中国肥胖预防和控制蓝皮书. 北京: 北京大学医学出版社, 2019.
[12]	Lee PH, Fu H, Lai TC, et al. Glycemic Control and the Risk of Tuberculosis: A Cohort Study. PLoS Medicine, 2016, 13(8):e1002072. doi: 10.1371/journal.pmed.1002072. doi: 10.1371/journal.pmed.1002072
[13]	葛均波, 徐永健. 内科学. 8版. 北京: 人民卫生出版社, 2013.
[14]	诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版). 中华健康管理学杂志, 2017, 11(1):7-28. doi: 10.3760/cma.j.issn.1674-0815.2017.01.003. doi: 10.3760/cma.j.issn.1674-0815.2017.01.003
[15]	Wang P, Pradhan K, Zhong XB, et al. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B, 2016, 6(5):384-392. doi: 10.1016/j.apsb.2016.07.014. doi: 10.1016/j.apsb.2016.07.014 URL
[16]	Ahadpour M, Eskandar MR, Mashayekhi V, et al. Mitochondrial oxidative stress and dysfunction induced by isoniazid: Study on isolated rat liver and brain mitochondria. Drug Chem Toxicol, 2016, 39(2):224-232. doi: 10.3109/01480545.2015.1092039. doi: 10.3109/01480545.2015.1092039 pmid: 26461142
[17]	Zhang T, Ikejima T, Li L, et al. Impairment of Mitochondrial Biogenesis and Dynamics Involved in Isoniazid-Induced Apoptosis of HepG2 Cells Was Alleviated by p38 MAPK Pathway. Front Pharmacol, 2017, 8:753. doi: 10.3389/fphar.2017.00753. doi: 10.3389/fphar.2017.00753 URL
[18]	Zhang TG, Ikejima T, Hayashi T, et al. AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells. J Appl Toxicol, 2017, 37:1219-1224. doi: 10.1002/jat.3483. doi: 10.1002/jat.3483 URL
[19]	Liu X, Zhao M, Mi J, et al. Protective Effect of Bicyclol on Anti-Tuberculosis Drug Induced Liver Injury in Rats. Molecules, 2017, 22(4):524. doi: 10.3390/molecules22040524. doi: 10.3390/molecules22040524 URL
[20]	Zhang T, Du J, Yin X, et al. Adverse Events in Treating Smear-Positive Tuberculosis Patients in China. Int J Environ Res Public Health, 2016, 13(1):86. doi: 10.3390/ijerph13010086. doi: 10.3390/ijerph13010086 URL
[21]	吴玉华, 武谦虎. 抗结核药致肝损害1949例文献分析. 西北药学杂志, 2015, 30(6):750-753. doi: 10.3969/j.issn.1004-2407.2015.06.028. doi: 10.3969/j.issn.1004-2407.2015.06.028
[22]	候清涛, 李芸, 李舍予, 等. 全球糖尿病疾病负担现状. 中国糖尿病杂志, 2016, 24(1):92-96. doi: 10.3969/j.issn.1006-6187.2016.01.023. doi: 10.3969/j.issn.1006-6187.2016.01.023
[23]	Singanayagam A, Sridhar S, Dhariwal J, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med, 2012, 185(6):653-659. doi: 10.1164/rccm.201105-0850OC. doi: 10.1164/rccm.201105-0850OC URL
[24]	Martinez L, Zhu L, Castellanos ME, et al. Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study. Clin Infect Dis, 2017, 65(12):2060-2068. doi: 10.1093/cid/cix632. doi: 10.1093/cid/cix632 URL
[25]	李永红, 李红恩, 雷世鑫, 等. 抗结核药致中国人群药物性肝损伤危险因素的Meta分析. 中国抗生素杂志, 2021, 46(6):628-633. doi: 10.13461/j.cnki.cja.007056. doi: 10.13461/j.cnki.cja.007056
[26]	吴启文, 姚叶萍, 赖小丽. 92例抗结核药物致肺结核患者肝损伤的临床特征分析. 中国新药与临床杂志, 2020, 39(7):417-420. doi: 10.14109/j.cnki.xyylc.2020.07.09. doi: 10.14109/j.cnki.xyylc.2020.07.09
[27]	何涛, 汪峰, 唐武. 抗结核药致药物性肝损伤危险因素的logistic回归分析. 中国药房, 2016, 27(12):1626-1628. doi: 10.6039/j.issn.1001-0408.2016.12.15. doi: 10.6039/j.issn.1001-0408.2016.12.15
[28]	杨学敏, 沈宝荣, 刘鹏园, 等. 抗结核药致药物性肝损伤危险因素的Logistic回归分析. 中国医院药学杂志, 2019, 39(1):67-71. doi: 10.13286/j.cnki.chinhosppharmacyj.2019.01.15. doi: 10.13286/j.cnki.chinhosppharmacyj.2019.01.15
[29]	程亮, 陈惠芬, 高爱霞, 等. 无锡地区一线口服抗结核药物所致药物性肝损伤多因素分析. 临床肺科杂志, 2018, 23(7):1172-1174. doi: 10.3969/j.issn.1009-6663.2018.07.003. doi: 10.3969/j.issn.1009-6663.2018.07.003
[30]	赵红, 程澄, 谢雯. 抗结核药物致肝损伤的发病机制. 中国肝脏病杂志(电子版), 2015, 7(4):11-13. doi: 10.3969/j.issn.1674-7380.2015.04.005. doi: 10.3969/j.issn.1674-7380.2015.04.005
[31]	Ishikawa M, Moriya S, Yokoyama T. Relationship between diet-related indicators and overweight and obesity in older adults in rural Japan. J Nutr Health Aging, 2017, 21(7):759-765. doi: 10.1007/s12603-016-0807-x. doi: 10.1007/s12603-016-0807-x pmid: 28717805
[32]	Sun L, Luo C, Long J, et al. Acrolein is a mitochondrial toxin: effects on respiratory function and enzyme activities in isolated rat liver mitochondria. Mitochondrion, 2006, 6(3):136-142. doi: 10.1016/j.mito.2006.04.003. doi: 10.1016/j.mito.2006.04.003 URL

基本特征	肝损伤组(53例)	无肝损伤组(405例)	χ²值	P值
年龄(岁)			0.238	0.626
≥60	15(28.3)	128(31.6)
<60	38(71.7)	277(68.4)
性别			1.194	0.274
男性	43(81.1)	351(86.7)
女性	10(18.9)	54(13.3)
婚姻状况			0.164	0.686
已婚	45(84.9)	352(86.9)
未婚/离异/丧偶	8(15.1)	53(13.1)
文化水平			3.535	0.316
小学及以下	17(32.1)	97(23.9)
初中	17(32.1)	143(35.3)
高中/职专	9(17.0)	106(26.2)
大专/职大及以上	10(18.8)	59(14.6)
职业			2.065	0.559
家务/待业/退休	12(22.6)	124(30.6)
农民	6(11.4)	36(8.9)
工人	15(28.3)	90(22.2)
其他^a	20(37.7)	155(38.3)
吸烟			4.422	0.035
是	31(58.5)	175(43.2)
否	22(41.5)	230(56.8)
基本特征	肝损伤组(53例)	无肝损伤组(405例)	χ²值	P值
饮酒			5.486	0.019
是	33(62.3)	183(45.2)
否	20(37.7)	222(54.8)
体力活动水平			10.832	0.004
轻度	38(71.7)	276(68.2)
中等	9(17.0)	117(28.9)
重度	6(11.3)	12(2.9)
体质量指数			12.659	0.005
<18.5	13(24.5)	35(8.6)
18.5~	25(47.2)	225(55.6)
24.0~	12(22.6)	118(29.1)
≥28.0	3(5.7)	27(6.7)
痰涂片			5.886	0.208
阴性	16(30.2)	114(28.1)
+	8(15.1)	75(18.5)
	2(3.8)	46(11.4)
+	3(5.7)	38(9.4)
	24(45.2)	132(32.6)
患者类型			1.011	0.315
复治	12(22.6)	69(17.0)
初治	41(77.4)	336(83.0)
使用保肝药			0.002	0.969
是	42(79.2)	320(79.0)
否	11(20.8)	85(21.0)
保肝药使用种类			1.701	0.427
0种	11(20.8)	85(21.0)
1~2种	28(52.8)	243(60.0)
3种及以上	14(26.4)	77(19.0)

变量	赋值	变量	赋值
血糖控制不良	否=0,是=1	体质量指数	≥18.5=0,<18.5=1
吸烟	否=0,是=1	保肝药使用情况	否=0,是=1
饮酒	否=0,是=1	贫血	否=0,是=1
体力活动水平	轻度=0,中/重度=1	膳食多样性	适中/充足=0,不足=1